Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1
Update: 2025-08-07
Description
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).
In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!
Click below to complete the claim your CE credit:
Module 1: bit.ly/49NCaQu
Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC
Module 2: bit.ly/405xEJO
In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!
Click below to complete the claim your CE credit:
Module 1: bit.ly/49NCaQu
Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC
Module 2: bit.ly/405xEJO
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
